What is the official ID of this bill?
The official print number for this legislation is HR 3285.
Fair Drug Prices: Lower Costs for Patients
This bill aims to reduce medication costs for patients. It sets limits on patient cost-sharing for drugs that receive high rebates from manufacturers, meaning patients will pay less for these specific medications. These changes are set to take effect from January 1, 2025.
Key points
Cost-sharing limits for highly rebated drugs: Insurers and pharmacy benefit managers cannot charge excessive amounts for drugs with significant manufacturer rebates.
Lower out-of-pocket costs: If a drug has high manufacturer rebates, your 30-day supply cost-sharing will be capped based on the annual net price of the drug.
Rebate transparency: Manufacturer rebates must be reflected at the point of sale if a highly rebated drug was previously excluded from coverage and is now covered.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.